Ipramol Steri-Neb (Ipratropium Bromide, Salbutamol)

Ipratropium bromide blocks muscarinic receptors, preventing acetylcholine‑induced bronchoconstriction, while salbutamol activates β2‑adrenergic receptors, causing smooth‑muscle relaxation. The dual mechanism produces additive bronchodilation, quickly opening narrowed airways in obstructive lung conditions.

The prescribed dose is determined by the treating clinician based on the patient’s age, disease severity, and response to therapy. The prescriber selects the volume of nebulizer solution and frequency of administration that best manages the individual’s respiratory symptoms.

Safety data in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any possible risk to the fetus or infant. Clinicians should discuss individual circumstances and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Compared with a nebulized salbutamol alone, Ipramol Steri‑Neb adds ipratropium’s anticholinergic effect, offering broader bronchodilation and potentially better symptom control in severe asthma or COPD. The combination may reduce the need for higher doses of a single agent and improve overall lung function.

Store the nebulizer solution at room temperature, preferably below 25 °C. Keep it in the original container, protect it from light, moisture, and extreme temperatures. Do not freeze the product, and discard any solution that appears discolored or contains particles.

The solution is added to a compatible nebulizer cup according to the prescribed volume, then connected to a nebulizer device. The patient inhales the aerosolized medication through a mouthpiece or mask, typically for several minutes until the dose is fully delivered.

Serious adverse events include paradoxical bronchospasm, severe tachycardia or arrhythmias, angioedema, and anaphylactic reactions. Patients should seek immediate medical attention if they experience worsening breathing, rapid heartbeat, swelling of the face or throat, or any signs of an allergic reaction.

The product is contraindicated in individuals with known hypersensitivity to ipratropium, salbutamol, or any excipients in the formulation. It should also be avoided in patients with narrow‑angle glaucoma, severe urinary retention, or those for whom β2‑agonists are medically prohibited.